To compare survival in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) treated with gefitinib 250 or 500 mg/day or standard methotrexate.
INTRODUCTION
Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) have a poor prognosis with mean survival of approximately 6 months.
1,2 Chemotherapy with platinumcontaining regimens combined with fluorouracil or taxanes is frequently the only available treatment. However, many patients have already received these agents either as induction treatment or as part of chemoradiation. Effective second-line chemotherapy options are limited and single-agent methotrexate continues to be used and remains a standard comparator for phase III studies. 1, 3 SCCHN tumors almost invariably express epidermal growth factor receptor (EGFR), and overexpression of this receptor has been associated with poor prognosis. [4] [5] [6] [7] [8] Gefitinib (IRESSA; AstraZeneca, Charnwood, Leicestershire, United Kingdom) blocks the tyrosine kinase domain of EGFR. A phase II trial of gefitinib 500 mg/day demonstrated a response rate of 10.6% and median survival of 8.1 months. 9 A second phase II trial using gefitinib 250 mg/day recorded a lower response rate of 1.4% and median survival of 5.5 months. 10 Based on these trials, gefitinib was well tolerated, could be taken for extended periods and may offer comparable or superior palliation to standard chemotherapy. This phase III trial compared the efficacy and safety of gefitinib (250 or 500 mg/day) versus methotrexate in patients with recurrent SCCHN.
PATIENTS AND METHODS

Eligibility
Patients with recurrent and/or metastatic SCCHN after radical radiation therapy (as primary treatment or postoperatively, with or without concomitant platinum-based chemotherapy), not amenable to salvage surgery or radiation therapy, were eligible. There were no restrictions on prior platinum-based chemotherapy. Full inclusion and exclusion criteria are in online-only Appendix.
Overall Study Design
This phase III randomized stratified multicenter study compared gefitinib 250 or 500 mg/day with methotrexate 40 mg/m 2 . The primary end point was overall survival; secondary end points were objective response rate (ORR), quality of life (QOL), symptom improvement, and safety. Exploratory end points included association of efficacy with EGFR gene copy number and gefitinib pharmacokinetics. Physicians and patients were blinded to gefitinib dose. The study was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonisation, and Good Clinical Practice. All patients provided signed informed consent.
Patients were stratified into two groups (by combination of objective criteria and investigator judgment). Group A had stable or progressive disease after Ն two cycles of platinum-based chemotherapy for recurrent disease, Group B was considered unsuitable for platinum-containing chemotherapy.
Patients received gefitinib or methotrexate until disease progression, toxicity, or withdrawal of consent. Cross-over to alternative treatment after discontinuing study treatment was discouraged.
Overall survival was assessed from date of random assignment to date of patient death due to any cause, or censored at last date the patient was known to be alive. Median follow-up was defined as time from random assignment to death or censoring. Tumor response was evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) 11 every 8 weeks. Symptom improvement and QOL were assessed using the Functional Assessment of Cancer Therapy-Head & Neck (FACT-H&N) symptom index (FHNSI-10) and the FACT-H&N questionnaire, respectively. 12,13 The trial outcome index (TOI, sum of FACT-H&N physical well-being ϩ functional well-being ϩ additional concerns [ACS] subscales) was calculated. Improvement was defined as a change from baseline score of Ն 3 for FHNSI-10, Ն 7 for FACT-H&N total score, and Ն 6 for the TOI. Adverse events (AEs) were recorded according to the National Cancer Institute Common Terminology Criteria (CTC) version 3.0.
Treatment and Pharmacokinetics
Gefitinib was given daily as two 250-mg tablets or one 250-mg tablet with matching placebo to ensure blinding. Dispersible gefitinib formulations were used in patients with feeding tubes or swallowing difficulties. Gefitinib dose interruptions were allowed to manage associated toxicity, except for interstitial lung disease (ILD), which was an indication for immediate study withdrawal regardless of CTC grade. Full details of criteria for dose interruptions, delays, increases and reductions are included in Appendix. Methotrexate was injected weekly as an intravenous push starting at 40 mg/m 2 with a progressive increase to 60 mg/m 2 , if tolerated. For the first 6 months, trough plasma gefitinib levels were measured monthly in patients randomly assigned to gefitinib (Appendix). 
Measurement of EGFR Biomarkers
EGFR biomarkers were analyzed in patients with a tissue sample available before starting study therapy. EGFR gene copy number was measured by fluorescence in situ hybridization (FISH) using LSI EGFR SpectrumOrange/ CEP7 SpectrumGreen probe (Vysis, Abbott Laboratories, Abbott Park, IL).
14 According to the frequency of tumor cells with specific numbers of copies of EGFR gene and chromosome 7 centromere, patients were considered to have a high gene copy number (EGFR FISH-positive) if they had polysomy (Ն 4 copies in Ն 40% of cells) or gene amplification (ratio of gene/chromosome per cell Ն 2, presence of tight EGFR gene clusters, or Ն 15 copies of EGFR per cell in Ն 10% of analyzed cells). HER2 gene copy number was measured by FISH using PathVysion HER-2 DNA probe kit (Abbott Molecular, Abbott Park, IL) and the same scoring criteria for the EGFR gene.
14 The investigators measuring these biomarkers were unaware of the patient's random assignment or the clinical outcome.
EGFR expression was assessed by immunohistochemistry using the Dako EGFR pharmDx kit (Dako North America Inc, Carpinteria, CA) in tissue samples and according to EGFR immunohistochemical guidelines. 15 Patients were classified as EGFR positive if their tumor samples had Ն 10% cells stained for EGFR (based on analysis in patients with non-small-cell lung cancer [NSCLC] 16 and similar to other reported studies involving SCCHN tissues 17 ).
Statistics
Two coprimary analyses compared overall survival between each gefitinib dose and methotrexate using a stratified log-rank test with adjustment for random assignment stratification factor. For each comparison, the goal was to have a 90% power with an overall type 1 error rate of 5% to test the hypothesis that gefitinib improved survival by 50% (assuming median survival of 4 months for methotrexate 18 and 6 months for gefitinib), translating to a hazard ratio (HR) of 0.67 for gefitinib relative to methotrexate. A total of 384 cumulative deaths were required for the final analysis. For each coprimary analysis, the effects of each gefitinib dose relative to methotrexate were estimated and Hochberg's procedure 19 was employed, if required, to preserve the overall type I error rate at 5%. Survival distributions were estimated using the Kaplan-Meier method. In a subsidiary analysis, time to death was analyzed by Cox's proportional hazards regression, with terms included to allow for the effects of randomized treatment and stratified subpopulation. Response rates were calculated for each treatment arm and compared using a 2 test, stratifying for randomization strata.
RESULTS
Patient Characteristics
Between December 2003 and January 2006, 564 patients from 123 centers worldwide were screened and 486 were randomly assigned to gefitinib 250 mg (158 patients), gefitinib 500 mg (167 patients), or methotrexate (161 patients; Fig 1) . The treatment arms were well balanced for age, race, performance status (PS), and primary disease sites (Table 1) .
Not surprisingly, there were some differences in the demographic characteristics between patients stratified to Group A (platinumresistant disease) and Group B (unsuitable for platinum-containing chemotherapy). Patients in Group A tended to have a better PS (WHO PS 0-1, 85% v 72%), were generally younger (age Ͻ 65 years, 77% v 64%), and had a longer time from diagnosis to random assignment (Ն 36 months, 28% v 16%) than patients in Group B.
Thirty-eight percent of gefitinib patients and 30% of methotrexate patients received further treatment after leaving the study. Approximately 20% of patients randomly assigned to gefitinib subsequently received methotrexate, and 7% of patients randomly assigned to methotrexate later received gefitinib.
Overall Survival
Overall mortality was 78.6% (382 patients) at median follow-up of 6.2 months. There was no significant difference in overall survival between treatment arms. Median survival in patients receiving gefitinib 250 mg, gefitinib 500 mg, and methotrexate was 5.6, 6.0, and 6.7 months, respectively; HR ϭ 1.22 for gefitinib 250 mg versus methotrexate (95% CI, 0.95 to 1.57; P ϭ .12) and HR ϭ 1.12 for gefitinib 500 mg versus methotrexate (95% CI, 0.87 to 1.43; P ϭ .39). One-year survival for gefitinib 250 mg, gefitinib 500 mg, and methotrexate was 16.7%, 17.8%, and 26.5%, respectively (Fig 2) .
In Group A (platinum-resistant disease) there appeared to be an advantage for methotrexate over both doses of gefitinib (HR, 1.62 for gefitinib 250 mg v methotrexate; 95% CI, 1.13 to 2.32; P ϭ .01; HR ϭ 1.50 for gefitinib 500 mg v methotrexate; 95% CI, 1.06 to 2.13; P ϭ .02; Fig 3) . The survival curves for Group B (unsuitable for platinum chemotherapy) appeared to demonstrate little difference between treatment arms.
Response to Treatment
Tumor response was assessed in 456 patients (94%; Table 2 ). ORRs were 2.7%, 7.6%, and 3.9% in the gefitinib 250 mg, gefitinib 500 mg, and methotrexate groups, respectively. The odds ratio was 0.69 (95% CI, 0.19 to 2.50; P ϭ .57) for gefitinib 250 mg, and 2.04 (95% CI, 0.74 to 5.56; P ϭ .17) for gefitinib 500 mg, versus methotrexate.
QOL and Symptom Improvement
Compliance (number of assessable forms/number of expected forms) was approximately 70% with the FHNSI-10 and the FACT-H&N questionnaires at baseline in each treatment group and overall compliance was approximately 60%. More than 90% of forms were assessable.
QOL improvement rates (FACT-H&N total score) were 13.4%, 18.0%, and 6.0% for gefitinib 250 mg, gefitinib 500 mg, and methotrexate, respectively; similar results were obtained using the TOI (11.3%, 18.9%, and 8.3%, respectively). Analysis of mean change from baseline score showed no statistically or clinically significant differences between either gefitinib dose and methotrexate for FACT-H&N total score or TOI. Symptom improvement rates (FHNSI-10) were 0 Overall Survival (probability)
Time Since Random Assignment (months) 
Pharmacokinetics
Of 169 patients with assessable plasma concentration data, an approximately two-fold difference in mean predicted steady-state trough levels between gefitinib 250 and 500 mg was observed although there was considerable overlap in the ranges of value. Mean predicted trough plasma concentrations of gefitinib were 305 ng/mL (range, 37 to 874 ng/mL; standard deviation 175) and 594 ng/mL (range, 120 to 1,338 ng/mL; standard deviation, 260) in patients receiving 250 and 500 mg, respectively. Gefitinib pharmacokinetics were not affected by random assignment to stratum A or B, EGFR gene copy number or the administration route (121 patients received 250 mg gefitinib as a tablet, 33 as a dispersed tablet, and three of both formulations; 115 patients received 500 mg gefitinib as a tablet, 45 as a dispersed tablet, and six of both formulations). Interpatient variability in gefitinib pharmacokinetics was similar in magnitude to those observed in previous studies but the mechanisms underlying the variability have not been elucidated (unpublished observations).
EGFR Biomarker Analysis
EGFR gene copy number was measured in 212 patients. These patients were representative of the overall study population (except that EGFR gene copy number was only known in one patient of Asian descent) and key demographic and baseline characteristics were well balanced between treatment arms. The incidence of EGFR FISHpositive patients was 45% in the gefitinib 250-mg arm (29 of 64 patients); 41% in the gefitinib 500-mg arm (30 of 74 patients); and 34% in the methotrexate arm (25 of 74 patients). Median survival for EGFR FISH-positive patients receiving gefitinib 250 mg, gefitinib 500 mg, and methotrexate was 6.1, 5.9, and 7.6 months, respectively (Fig  4) . Median survival in EGFR FISH-negative patients was 6.0, 6.0, and 6.8 months, respectively. There was no significant difference in overall survival for EGFR FISH-positive patients treated with gefitinib compared with methotrexate (gefitinib 250 mg v methotrexate: HR, 1.02; 95% CI, 0.54 to 1.90; P ϭ .96; gefitinib 500 mg v methotrexate: HR, 1.30; 95% CI, 0.71 to 2.37; P ϭ .39). A similar result was seen for EGFR FISH-negative patients.
EGFR FISH-positive patients appeared to have a higher ORR with gefitinib 500 mg (13.8%, four of 29 patients) compared with gefitinib 250 mg (3.6%, one of 28 patients), and methotrexate (zero of 23 patients). No appreciable difference in response was detected between treatment arms among EGFR FISH-negative patients (zero of 33 patients, gefitinib 250 mg; 4.8% [two of 42 patients], gefitinib 500 mg; 6.4% [three of 47 patients], methotrexate). However, the numbers of responders in these analyses are small and the data should be interpreted with caution. HER2 gene copy number did not predict for clinical outcome across the three treatment arms.
Of patients who provided a tissue sample, EGFR protein expression was measured in 248 tissue samples. The proportion of EGFR expression-positive patients at the predefined Ն 10% positive cells cutoff level was 99.6% and so no formal analyses were performed.
Safety
Safety data were available for 483 (99%) patients. Median exposure was 71, 81, and 58 days for gefitinib 250 mg, gefitinib 500 mg, and methotrexate, respectively. The most common AEs with gefitinib (dose blinded) were rash, diarrhea, cancer pain, nausea, and vomiting, and with methotrexate were stomatitis, nausea, and constipation (Table 3) .
For gefitinib 250 mg, gefitinib 500 mg, and methotrexate, respectively, the incidence of dose interruptions due to AEs was 21%, 28%, and 47%; treatment-related CTC grade 3 to 5 AEs was 10%, 20%, and 35%; withdrawals due to AEs was 8%, 8%, and 14%; and treatmentrelated AEs leading to death was 0.6%, 0%, and 2.5%.
Tumor hemorrhage-type events were more common with gefitinib (250 and 500 mg) than with methotrexate, (8.9% [14 patients], 11.4% [19 patients] , and 1.9% [three patients], respectively). The majority of tumor hemorrhage events were considered mild to moderate (CTC grade 1 or 2) and the majority resolved while study treatment continued. Three patients died as a result of tumor hemorrhage (two on gefitinib 250 mg, one on gefitinib 500 mg); none of these deaths were considered related to gefitinib treatment.
ILD events were reported with similar frequency in each arm: two patients (1.3%) on gefitinib 250 mg (both CTC grade 2), two patients (1.2%) on gefitinib 500 mg (one CTC grade 1, one CTC grade 2), and two patients (1.3%) on methotrexate (one CTC grade 1, one CTC grade 3).
DISCUSSION
This study in relapsed SCCHN demonstrated ORRs for gefitinib 500 and 250 mg of 7.6% and 2.7%, respectively, which are similar to the 10.6% and 1.4% ORRs previously recorded. 9, 10 This dose response is consistent with the two-fold increase in gefitinib plasma levels seen in this study, but is not observed in phase II advanced NSCLC studies (Iressa Dose Evaluation in Advanced Lung Cancer [IDEAL] studies 1 and 2). 20, 21 The ORR to methotrexate of 3.9% determined by RECIST was lower than recorded in previous phase III studies in which ORRs determined by WHO criteria ranged from 6% to 36%. 1, 3, [22] [23] [24] Although the ORR was higher with gefitinib 500 mg than with methotrexate, this difference did not reach statistical significance.
Gefitinib and methotrexate have different toxicity profiles. Methotrexate produced stomatitis (34.6%) and nausea (23.9%), which were generally mild, although severe stomatitis (Ն grade 3) occurred in 10% of patients. The most common AEs reported with gefitinib 250 and 500 mg were skin rash (29% and 39%, respectively) and diarrhea (25.9% and 39.2%, respectively).
Dose interruptions from AEs occurred in 20.9%, 28.3%, and 47.2% of gefitinib 250 mg, gefitinib 500 mg, and methotrexate patients whereas the proportions of patients withdrawing from the study from AEs were 8.2%, 7.8%, and 13.8%. Patients randomly assigned to gefitinib therefore tended to remain on study medication, with median time on study medication in the three arms being 71, 81, and 58 days. The increased time on study medication with gefitinib may have influenced both the chance of response and of developing studyrelated AEs. In general, gefitinib demonstrated ORRs consistent with previous reports, an acceptable toxicity profile and appeared to be well tolerated. This was supported by a trend to improvement in QOL measures in patients randomly assigned to gefitinib, although these improvements were not statistically significant. QOL improvement rates (FACT-H&N total scores) were 13.4%, 18.0%, and 6.0% for gefitinib 250 mg, gefitinib 500 mg, and methotrexate, respectively. These data should be viewed in the context of the amount of missing Abbreviation: CTC, National Cancer Institute Common Terminology Criteria. *Tumor hemorrhage-type events (including hemorrhagic tumor necrosis, tumor hemorrhage, mouth hemorrhage, pharyngeal hemorrhage, tonsillar hemorrhage, and tongue hemorrhage) were reported by 14 patients (8.9%) receiving gefitinib 250 mg, 19 patients (11.4%) receiving gefitinib 500 mg, and three patients (1.9%) receiving methotrexate. data resulting from technical issues with the electronic diary data capture tool.
The primary end point for this study was overall survival. Gefitinib is an oral drug with a favorable toxicity profile and can be taken for extended periods. It was envisaged that gefitinib, even with a relatively low ORR, would induce disease stabilization leading to improved survival. Previous studies have reported that patients receiving gefitinib often developed tumor stabilization even if they did not achieve a tumor response. The term "disease control rate" is often used to describe the proportion of patients with response or stable disease. Gefitinib, despite a numerically superior ORR and greater treatment duration, did not increase overall survival, in fact, this was numerically superior in the methotrexate arm. The number of patients who received poststudy therapy was broadly similar between the treatment groups and the cross-over rate from gefitinib to methotrexate and from methotrexate to gefitinib was relatively low.
Two unexpected types of AEs in the gefitinib arms were cancerassociated pain and tumor hemorrhage. Cancer pain occurred in 19.0%, 18.1%, and 11.3% of patients receiving gefitinib 250 mg, gefitinib 500 mg, and methotrexate, respectively, and tumor hemorrhage-type events occurred in 8.9%, 11.4% , and 1.9% of patients, respectively. The difference in the incidence of cancer pain was no longer apparent when corrections are made for time on treatment. Most cases of tumor hemorrhage were mild. Three gefitinib-treated patients died as a result of tumor hemorrhage; none of these deaths were attributed to gefitinib.
To our knowledge, this is the first randomized phase III study for SCCHN in which EGFR gene copy number has been evaluated using FISH in patients treated with an anti-EGFR therapy. Eighty-four tumors (39.6%) had high EGFR gene copy number and EGFR gene copy number was not shown to be statistically significantly correlated with survival. However, EGFR gene copy number has been reported as a poor prognostic factor in SCCHN, 8, 25 therefore the similar survival rates between FISH-positive and FISH-negative patients in this study are noteworthy. It is appropriate to note that the cutoff value used to define FISH-positive patients was based on historical data from similar analyses among patients with NSCLC. Further studies are needed to establish whether these cutoff values are appropriate in SCCHN. Tumors with increased EGFR gene copy number appeared to have an increased chance of responding to gefitinib 500 mg (13.8%) compared with EGFR FISH-negative tumors (4.8%).
In patients with recurrent or metastatic SCCHN, while responses with gefitinib were seen, neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate. With the exception of tumor hemorrhage-type events with gefitinib, the adverse event profiles were generally consistent with those previously observed. In Table 4 , under "Phase II ϩ Phase III (early and late onset)," the data were inadvertently transposed between "presence of centrally located tumor" and "presence of centrally located node."
AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
The online version has been corrected in departure from the print. In the Patients and Methods section, under Overall Study Design, CTC was defined in the last sentence as Common Toxicity Criteria, whereas it should have been Common Terminology Criteria.
In Table 3 , CTC was also defined as Common Toxicity Criteria and should have been Common Terminology Criteria.
In Figure 1 , the following footnote was inadvertently omitted: "Evaluable for efficacy, all randomized patients; Evaluable for response, patients with unidimensional measurable disease at baseline as per the Response Evaluation Criteria In Solid Tumors (RECIST) criteria; Evaluable for safety, all patients who received at least 1 dose of study treatment; Evaluable for quality of life, patients with an evaluable baseline quality of life assessment and at least 1 evaluable post-baseline quality of life assessment."
In the legend of Figure 4 , parts A and B were mislabeled and should have been: (A) EGFR FISH-positive; (B) EGFR FISH-negative.
In the Contributions section, Ezra E.W. Cohen should have been acknowledged for collection and assembly of data.
The online only Appendix was inadvertently omitted. The online version has been corrected in departure from the print. (J Clin Oncol 27:1948 -1955 , 2009 ), contained errors in some of the data given for PFS and OS.
In the Results section, under Experimental Versus Control Arms, the third and fifth sentences were given as: "For PFS, the experimental treatment provided a benefit in both PS 0 to 1 patients (HR ϭ 0.81 for experimental v control treatment; 95% CI, 0.77 to 0.86; P Ͻ .00001; median PFS, 17.9 months for experimental treatment v 16.4 months for control) and PS2
